| Verfasst von: | Spencer, Andrew [VerfasserIn] |
|---|---|
| Moreau, Philippe [VerfasserIn] | |
| Mateos, Maria-Victoria [VerfasserIn] | |
| Goldschmidt, Hartmut [VerfasserIn] | |
| Suzuki, Kenshi [VerfasserIn] | |
| Levin, Mark-David [VerfasserIn] | |
| Sonneveld, Pieter [VerfasserIn] | |
| Orlowski, Robert Z. [VerfasserIn] | |
| Yoon, Sung-Soo [VerfasserIn] | |
| Usmani, Saad Z. [VerfasserIn] | |
| Weisel, Katja [VerfasserIn] | |
| Reece, Donna [VerfasserIn] | |
| Ahmadi, Tahamtan [VerfasserIn] | |
| Pei, Huiling [VerfasserIn] | |
| Mayo, Wendy Garvin [VerfasserIn] | |
| Gai, Xue [VerfasserIn] | |
| Carey, Jodi [VerfasserIn] | |
| Bartlett, J. Blake [VerfasserIn] | |
| Carson, Robin [VerfasserIn] | |
| Dimopoulos, Meletios A. [VerfasserIn] | |
| Titel: | Daratumumab for patients with myeloma with early or late relapse after initial therapy |
| Titelzusatz: | subgroup analysis of CASTOR and POLLUX |
| Verf.angabe: | Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z. Orlowski, Sung-Soo Yoon, Saad Z. Usmani, Katja Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J. Blake Bartlett, Robin Carson, and Meletios A. Dimopoulos |
| E-Jahr: | 2024 |
| Jahr: | January 23 2024 |
| Umfang: | 11 S. |
| Illustrationen: | Illustrationen |
| Fussnoten: | Vorab veröffentlicht: 4. Dezember 2023 ; Gesehen am 12.11.2024 |
| Titel Quelle: | Enthalten in: Blood advances |
| Ort Quelle: | Washington, DC : American Society of Hematology, 2016 |
| Jahr Quelle: | 2024 |
| Band/Heft Quelle: | 8(2024), 2 vom: Jan., Seite 388-398 |
| ISSN Quelle: | 2473-9537 |
| Abstract: | High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS), regardless of cytogenetic risk, and achieved higher rates of complete response or better (≥CR) and minimal residual disease (MRD) negativity vs that with Vd/Rd alone in relapsed/refractory MM. Post hoc analyses of CASTOR and POLLUX evaluated patient subgroups with 1 prior line of therapy based on timing of progression/relapse (early or late) after initiation of first line of therapy. PFS consistently favored the daratumumab-containing regimens across subgroups using both a 24- and 18-month early-relapse cutoff. In the CASTOR/POLLUX pooled data set, daratumumab reduced the risk of disease progression or death by 65% (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.26-0.48; P < .0001) in the early-relapse (<24 months) subgroup and by 65% (HR, 0.35; 95% CI, 0.26-0.47; P < .0001) in the late-relapse (≥24 months) subgroup. OS also favored the daratumumab-containing regimens in both the early-relapse (HR, 0.62; 95% CI, 0.45-0.86; P = .0036) and late-relapse (HR, 0.67; 95% CI, 0.48-0.93; P = .0183) subgroups in the pooled population using a 24-month cutoff. Rates of ≥CR and MRD negativity (10−5) were higher with daratumumab vs control, regardless of progression/relapse timing. Although daratumumab is unable to fully overcome the adverse prognosis of early relapse, our results support the use of daratumumab for patients with 1 prior line of therapy, including for those who progress/relapse early after initial therapy and are considered to have functional high-risk MM. These trials were registered at www.clinicaltrials.gov as #NCT02136134 (CASTOR) and #NCT02076009 (POLLUX). |
| DOI: | doi:10.1182/bloodadvances.2023010579 |
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt. Volltext: https://doi.org/10.1182/bloodadvances.2023010579 |
| DOI: https://doi.org/10.1182/bloodadvances.2023010579 | |
| Datenträger: | Online-Ressource |
| Sprache: | eng |
| K10plus-PPN: | 1908281707 |
| Verknüpfungen: | → Zeitschrift |